Fulcrum Therapeutics Inc. (NASDAQ: FULC) reported Q1 EPS of ($0.43), $0.01 better than the analyst estimate of ($0.44).

Update to Cash Runway Guidance

Based on its current operating plans, Fulcrum now expects that its cash, cash equivalents, and marketable securities as of March 31, 2024, together with the $80.0 million upfront payment to be received from Sanofi under the collaboration and license agreement, will be sufficient to fund its operating requirements into 2027.

For earnings history and earnings-related data on Fulcrum Therapeutics Inc. (FULC) click here.